Atypical Uses of Atypical Antipsychotics

REFERENCES

• McDougle C J, Fleischmann R L, Epperson C N, et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995; 56: 526–8, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Steinert T, Schmidt-Michel P O, Kaschka W P. Considerable improvement in a case of obsessive-compulsive disorder in an emotionally unstable personality disorder, borderline type under treatment with clozapine. Pharmacopsychiatry 1996; 29: 111–4, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Potenza M N, Wasylink S, Epperson C N, McDougle C J. Olanzapine augmentation of fluoxetine in the treatment of trichotillomania. Am J Psychiatry 1998; 5: 1299–300, [CSA]
   Google Scholar
• Fitzgerald K D, Stewart C M, Tawile V, Rosenberg D R. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol 1999; 9: 115–23, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hanna G L, Fluent T E, Fischer D J. Separation anxiety in children and adolescents treated with risperidone. J Child Adolesc Psychopharmacol 1999; 9: 277–83, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiatry 1999; 156: 1834–5, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Degner D, Bleich S, Kornhuber J, Ruther E. Olanzapine treatment of obsessive-compulsive disorder. Can J Psychiatry 2000; 45: 393, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Kawahara T, Ueda Y, Mitsuyama Y. A case report of refractory obsessive-compulsive disorder improved by risperidone augmentation of clomipramine treatment. Psychiatry Clin Neurosci 2000; 59: 599–601, [CSA], [CROSSREF]
   Google Scholar
• Marusic A, Farmer A. Antidepressant augmentation with low-dose olanzapine in obsessive-compulsive disorder. Br J Psychiatry 2000; 177: 567, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Sun T F, Lin P Y, Wu C K. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases. Chang Gung Med J 2001; 24: 587–92, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Francobandiera G. Quetiapine augmentation of sertraline in obsessive-compulsive disorder. J Clin Psychiatry 2002; 63: 1046–7, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Matur Z, Ucok A. Quetiapine treatment in a patient with Tourette's syndrome, obsessive-compulsive disorder and drug-induced mania. Isr J Psychiatry Relat Sci 2003; 40: 150–2, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kumar S, Ng B, Howie W. The improvement of obsessive-compulsive symptoms in a patient with schizophrenia treated with clozapine. Psychiatry Clin Neurosci 2003; 57: 235–6, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Poyurovsky M, Kurs R, Weizman A. Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder. J Clin Psychiatry 2003; 64: 611, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cohen L S. Quetiapine in treatment-resistant obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2003; 42: 623–4, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kopala L, Honer W G. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 1994; 151: 1714–5, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dryden-Edwards R C, Reiss A L. Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. J Child Adolesc Psychopharmacol 1996; 6: 139–45, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Alzaid K, Jones B D. A case report of risperidone-induced obsessive-compulsive symptoms. J Clin Psychopharmacol 1997; 17: 58–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Andrade C. Risperidone may worsen fluoxetine-treated OCD. J Clin Psychiatry 1998; 59: 255–6, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Morrison D, Clark D, Goldfarb E, McCoy L. Worsening of obsessive-compulsive symptoms following treatment with olanzapine. Am J Psychiatry 1998; 155: 855, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Mottard J P, de la Sablonniere J F. Olanzapine-induced obsessive-compulsive disorder. Am J Psychiatry 1999; 156: 799–800, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Strous R D, Patel J K, Zimmet S, Green A I. Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features. Am J Psychiatry 1999; 156: 973–4, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lykouras L, Zervas I M, Gournellis R, et al. Olanzapine and obsessive-compulsive symptoms. Eur Neuropsychopharmacol 2000; 10: 385–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ramasubbu R, Ravindran A, Lapierre Y. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Pharmacopsychiatry 2000; 33: 236–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Khullar A, Chue P, Tibbo P. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci 2001; 26: 55–9, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Cheung E F. Obsessive-compulsive symptoms during treatment with clozapine in a patient with schizophrenia. Aust N Z J Psychiatry 2001; 35: 695–6, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Jonkers F, De Haan L. Olanzapine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder. Psychopharmacology 2002; 162: 87–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• McDougle C J, Barr L C, Goodman W K, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 1995; 152: 1812–4, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• McDougle C J, Epperson C N, Pelton G H, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 794–801, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002; 17: 115–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hamner M B. Clozapine treatment for a veteran with comorbid psychosis and PTSD. Am J Psychiatry 1996; 153: 841, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Abraham H D, Mamen A. LSD-like panic from risperidone in post-LSD visual disorder. J Clin Psychopharmacol 1996; 16: 238–41, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mandalos G E, Szarek B L. New-onset panic attacks in a patient treated with olanzapine. J Clin Psychopharmacol 1999; 19: 191, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bressan R A, Monteiro V B, Dias C C. Panic disorder associated with clozapine. Am J Psychiatry 2000; 157: 2056, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Etxebeste M, Aragues E, Malo P, Pacheco L. Olanzapine and panic attacks. Am J Psychiatry 2000; 157: 659–60, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Khaldi S, Kornriech C, Bernard D, Isidore P. Usefulness of olanzapine in refractory panic attacks. J Clin Psychopharmaology 2003; 23: 100–1, [CSA], [CROSSREF]
   Google Scholar
• Barnett S D, Kramer M L, Casat C D, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002; 16: 365–8, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shelton R C, Tollefson G D, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131–4, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Corya S A, Andersen S W, Detke H C, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry 2003; 64: 1349–56, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079–88, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Narendran R, Young C M, Valenti A M, et al. Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. J Clin Psychiatry 2001; 62: 509–16, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rothschild A J, Bates K S, Boehringer K L, Syed A. Olanzapine response in psychotic depression. J Clin Psychiatry 1999; 60: 116–8, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Nelson E B, Rielage E, Welge J A, Keck P E, Jr. An open trial of olanzapine in the treatment of patients with psychotic depression. Ann Clin Psychiatry 2001; 13: 147–51, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Zhang W, Perry K W, Wong D T, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000; 23: 250–62, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Papakostas G I, Petersen T J, Nierenberg A A, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004; 65: 217–21, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Aman M G, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1137–46, [CSA], [CROSSREF]
   Google Scholar
• Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Adolesc Psychiatry 2002; 41: 1026–36, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McDougle C J, Holmes J P, Bronson M R, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36: 685–93, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Potenza M N, Holmes J P, Kanes S J, et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacology 1999; 19: 37–44, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Adolesc Psychiatry 2001; 40: 1206–14, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kemner C, Willemsen-Swinkels S H, De Jonge M, et al. Open-label study of olanzapine in children with pervasive development disorder. J Clin Psychopharmacol 2002; 22: 455–60, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003; 64: 1039–47, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Stein D J, Bouwer C, Hawkridge S, Emsley R A. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997; 58: 119–22, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Margolese H C, Annable L, Dion Y. Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. J Clin Psychiatry 2002; 63: 1040–4, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Scahill L, Leckman J F, Schultz R T, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003; 60: 1130–5, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bruggeman R, van der Linden C, Buitelaar J K, et al. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001; 62: 50–6, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lombroso P J, Scahill L, King R A, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995; 34: 1147–52, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lavid N, Franklin D L, Maguire G A. Management of child and adolescent stuttering with olanzapine: three case reports. Ann Clin Psychiatry 1999; 11: 233–6, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Maguire G A, Riley G D, Franklin D L, Gottschalk L A. Risperidone for the treatment of stuttering. J Clin Psychopharmacol 2000; 20: 479–82, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bourgeois J A, Klein M. Risperidone and fluoxetine in the treatment of pedophilia with comorbid dysthymia. J Clin Psychopharmacol 1996; 16: 257–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gallucci G, Beard G. Risperidone and the treatment of delusions of parasitosis in an elderly patient. Psychosomatics 1995; 36: 578–80, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Safer D L, Wenegrat B, Roth W T. Risperidone in the treatment of delusional parasitosis: a case report. J Clinical Psychopharmacol 1997; 17: 131–2, [CSA], [CROSSREF]
   Google Scholar
• Cetin M, Ebrinc S, Agargun M Y, Yigit S. Risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Clin Psychiatry 1999; 60: 554, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Weintraub E, Robinson C. A case of monosymptomatic hypochondriacal psychosis treated with olanzapine. Ann Clin Psychiatry 2000; 12: 247–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Fawcett R G. Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis. J Clin Psychiatry 2002; 63: 169, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Phillips K A, Albertini R S, Siniscalchi J M, et al. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry 2001; 62: 721–7, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ashton A K. Olanzapine augmentation for trichotillomania. Am J Psychiatry 2001; 158: 1929–30, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stewart R S, Nejtek V A. An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. J Clin Psychiatry 2003; 64: 49–52, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand 2002; 105: 441–4, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zuddas A, Cianchetti C. Efficacy of risperidone in idiopathic segmental dystonia. Lancet 1996; 347: 127–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Bai Y, Yu S, Lin C. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64: 1342–8, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Alzaid K, Jones B D. A case report of risperidone-induced obsessive-compulsive symptoms. J Clin Psychopharmacol 1997; 17: 58–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Andrade C. Risperidone may worsen fluoxetine-treated OCD. J Clin Psychiatry 1998; 59: 255–6, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Cheung E F. Obsessive-compulsive symptoms during treatment with clozapine in a patient with schizophrenia. Aust N Z J Psychiatry 2001; 35: 695–6, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Cohen L S. Quetiapine in treatment-resistant obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2003; 42: 623–4, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Degner D, Bleich S, Kornhuber J, Ruther E. Olanzapine treatment of obsessive-compulsive disorder. Can J Psychiatry 2000; 45: 393, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Dryden-Edwards R C, Reiss A L. Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. J Child Adolesc Psychopharmacology 1996; 6: 139–45, [CSA]
   Google Scholar
• Fitzgerald K D, Stewart C M, Tawile V, Rosenberg D R. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol 1999; 9: 115–23, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Francobandiera G. Quetiapine augmentation of sertraline in obsessive-compulsive disorder. J Clin Psychiatry 2002; 63: 1046–7, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hanna G L, Fluent T E, Fischer D J. Separation anxiety in children and adolescents treated with risperidone. J Child Adolesc Psychopharmacol 1999; 9: 277–83, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Jonkers F, De Haan L. Olanzapine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder. Psychopharmacology 2002; 162: 87–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Kawahara T, Ueda Y, Mitsuyama Y. A case report of refractory obsessive-compulsive disorder improved by risperidone augmentation of clomipramine treatment. Psychiatry Clin Neurosci 2000; 59: 599–601, [CSA], [CROSSREF]
   Google Scholar
• Khullar A, Chue P, Tibbo P. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci 2001; 26: 55–9, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Kopala L, Honer W G. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 1994; 151: 1714–5, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kumar S, Ng B, Howie W. The improvement of obsessive- compulsive symptoms in a patient with schizophrenia treated with clozapine. Psychiatry Clin Neurosci 2003; 57: 235–6, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Lykouras L, Zervas I M, Gournellis R, et al. Olanzapine and obsessive-compulsive symptoms. Eur Neuropsychopharmacol 2000; 10: 385–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiatry 1999; 156: 1834–5, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Marusic A, Farmer A. Antidepressant augmentation with low-dose olanzapine in obsessive-compulsive disorder. Br J Psychiatry 2000; 177: 567, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Matur Z, Ucok A. Quetiapine treatment in a patient with Tourette's syndrome, obsessive-compulsive disorder and drug-induced mania. Isr J Psychiatry Relat Sci 2003; 40: 150–2, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• McDougle C J, Fleischmann R L, Epperson C N, et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995; 56: 526–8, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Morrison D, Clark D, Goldfarb E, McCoy L. Worsening of obsessive-compulsive symptoms following treatment with olanzapine. Am J Psychiatry 1998; 155: 855, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Mottard J P, de la Sablonniere J F. Olanzapine-induced obsessive-compulsive disorder. Am J Psychiatry 1999; 156: 799–800, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Potenza M N, Wasylink S, Epperson C N, McDougle C J. Olanzapine augmentation of fluoxetine in the treatment of trichotillomania. Am J Psychiatry 1998; 155: 1299–300, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Kurs R, Weizman A. Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder. J Clin Psychiatry 2003; 64: 611, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ramasubbu R, Ravindran A, Lapierre Y. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Pharmacopsychiatry 2000; 33: 236–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Steinert T, Schmidt-Michel P O, Kaschka W P. Considerable improvement in a case of obsessive-compulsive disorder in an emotionally unstable personality disorder, borderline type under treatment with clozapine. Pharmacopsychiatry 1996; 29: 111–4, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Strous R D, Patel J K, Zimmet S, Green A I. Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features. Am J Psychiatry 1999; 156: 973–4, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sun T F, Lin P Y, Wu C K. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases. Chang Gung Med J 2001; 24: 587–92, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• D' Amico G, Cedro C, Muscatello M R, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Progress Neuropsychopharmacol Biol Psychiatry 2003; 27: 619–23, [CSA], [CROSSREF]
   Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002; 17: 115–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 2000; 96: 91–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reputake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry 2002; 63: 700–3, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry 2001; 46: 356–8, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Jacobsen F M. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995; 56: 423–9, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Koran L M, Ringold A L, Elliott M A. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000; 61: 514–7, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Maina G, Albert U, Ziero S, Bogetto F. Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?. Int Clin Psychopharmacol 2003; 18: 23–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McDougle C J, Barr L C, Goodman W K, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 1995; 152: 1812–4, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• McDougle C J, Epperson C N, Pelton G H, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 794–801, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pfanner C, Marazziti D, Dell'Osso L, et al. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol 2000; 15: 297–301, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Saxena S, Wang D, Bystritsky A, Baxter L R, Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996; 57: 303–6, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Stein D J, Bouwer C, Hawkridge S, Emsley R A. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997; 58: 119–22, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Weiss E L, Potenza M N, McDougle C J, Epperson C N. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999; 60: 524–7, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Butterfield M I, Becker M E, Connor K M, et al. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol 2001; 16: 197–203, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hamner M B, Deitsch S E, Brodrick P S, et al. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 2003; 23: 15–20, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hamner M B, Faldowski R A, Ulmer H G, et al. Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol 2003; 18: 1–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Monnelly E P, Ciraulo D A, Knapp C, Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 2003; 23: 193–6, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Petty F, Brannan S, Casada J, et al. Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol 2001; 16: 331–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sokolski K N, Denson T F, Lee R F, et al. Quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorder. Mil Med 2003; 168: 486–9, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Stein M B, Kline N A, Matloff J L. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002; 159: 1777–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Eidelman I, Seedat S, Stein D J. Risperidone in the treatment of acute stress disorder in physically traumatized in-patients. Depress Anxiety 2000; 11: 187–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Filteau M J, Leblanc J, Bouchard R H. Quetiapine reduces flashbacks in chronic posttraumatic stress disorder. Can J Psychiatry 2003; 48: 282–3, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hamner M B. Clozapine treatment for a veteran with comorbid psychosis and PTSD. Am J Psychiatry 1996; 153: 841, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Krashin D, Oates E W. Risperidone as an adjunct therapy for post-traumatic stress disorder. Mil Med 1999; 164: 605–6, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Labbate L A, Douglas S. Olanzapine for nightmares and sleep disturbance in posttraumatic stress disorder (PTSD). Can J Psychiatry 2000; 45: 667–8, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Monnelly E P, Ciraulo D A. Risperidone effects on irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 1999; 19: 377–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Prior T I. Treatment of posttraumatic stress disorder with olanzapine. Can J Psychiatry 2001; 46: 182, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Sattar S P, Ucci B, Grant K, et al. Quetiapine therapy for posttraumatic stress disorder. Ann Pharmacother 2002; 36: 1875–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Abraham H D, Mamen A. LSD-like panic from risperidone in post-LSD visual disorder. J Clin Psychopharmacol 1996; 16: 238–41, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Barnett S D, Kramer M L, Casat C D, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002; 16: 365–8, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bressan R A, Monteiro V B, Dias C C. Panic disorder associated with clozapine. Am J Psychiatry 2000; 157: 2056, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Etxebeste M, Aragues E, Malo P, Pacheco L. Olanzapine and panic attacks. Am J Psychiatry 2000; 157: 659–60, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Khaldi S, Kornriech C, Bernard D, Isidore P. Usefulness of olanzapine in refractory panic attacks. J Clin Psychopharmaology 2003; 23: 100–1, [CSA], [CROSSREF]
   Google Scholar
• Mandalos G E, Szarek B L. New-onset panic attacks in a patient treated with olanzapine. J Clin Psychopharmacol 1999; 19: 191, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Corya S A, Andersen S W, Detke H C, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry 2003; 64: 1349–56, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hillert A, Maier W, Wetzel H, Benkert O. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome—a functional approach. Pharmacopsychiatry 1992; 25: 213–7, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hirose S, Ashby C R. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry 2002; 63: 733–6, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Jacobsen F M. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995; 56: 423–9, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Narendran R, Young C M, Valenti A M, Pristach C A, Pato M T, Grace J J. Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. J Clin Psychiatry 2001; 62: 509–16, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Nelson E B, Rielage E, Welge J A, Keck P E, Jr. An open trial of olanzapine in the treatment of patients with psychotic depression. Ann Clin Psychiatry 2001; 13: 147–51, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Ostroff R B, Nelson J C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60: 256–9, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Papakostas G I, Petersen T J, Nierenberg A A, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004; 65: 217–21, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rothschild A J, Bates K S, Boehringer K L, Syed A. Olanzapine response in psychotic depression. J Clin Psychiatry 1999; 60: 116–8, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shelton R C, Tollefson G D, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131–4, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stoll A L, Haura G. Tranylcypromine plus risperidone for treatment-refractory major depression. J Clin Psychopharmacol 2000; 20: 495–6, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079–88, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Viner M W, Chen Y, Bakshi I, Kamper P. Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation. J Clin Psychopharmacology 2003; 23: 104–6, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dassa D, Kaladjian A, Azorin J M, Giudicelli S. Clozapine in the treatment of psychotic refractory depression. Br J Psychiatry 1993; 163: 822–4, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Kaplan M. Atypical antipsychotics for treatment of mixed depression and anxiety. J Clin Psychiatry 2000; 61: 388–9, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Miodownik C, Lerner V. Risperidone in the treatment of psychotic depression. Clin Neuropharmacol 2000; 23: 335–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nacasch N, Dolberg O T, Hirschmann S, et al. Clozapine for the treatment of agitated-depressed patients with cognitive impairment: a report of three cases. Clin Neuropharmacol 1998; 21: 132–4, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Pitchot W, Ansseau M. Addition of olanzapine for treatment-resistant depression. Am J Psychiatry 2001; 158: 1737–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Ranjan R, Meltzer H Y. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1996; 40: 253–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Aman M G, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337–46, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fisman S, Steele M, Short J, et al. Case study: anorexia nervosa and autistic disorder in an adolescent girl. J Am Acad Child Adolesc Psychiatry 1996; 35: 937–40, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kemner C, Willemsen-Swinkels S H, De Jonge M, et al. Open-label study of olanzapine in children with pervasive development disorder. J Clin Psychopharmacol 2002; 22: 455–60, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• King B, Zwi K, Nunn K, Longworth J, Dossetor D. Use of risperidone in a paediatric population: an observational study. J Paediatr Child Health 2003; 39: 523–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Adolesc Psychiatry 2001; 40: 1206–14, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McDougle C J, Holmes J P, Bronson M R, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36: 685–93, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Potenza M N, Holmes J P, Kanes S J, et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999; 19: 37–44, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Adolesc Psychiatry 2001; 40: 1206–14, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003; 64: 1039–47, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Adolesc Psychiatry 2002; 41: 1026–36, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bruggeman R, van der Linden C, Buitelaar J K, et al. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001; 62: 50–6, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lavid N, Franklin D L, Maguire G A. Management of child and adolescent stuttering with olanzapine: three case reports. Ann Clin Psychiatry 1999; 11: 233–6, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Lombroso P J, Scahill L, King R A, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995; 34: 1147–52, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Maguire G A, Riley G D, Franklin D L, Gottschalk L A. Risperidone for the treatment of stuttering. J Clin Psychopharmacol 2000; 20: 479–82, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Margolese H C, Annable L, Dion Y. Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. J Clin Psychiatry 2002; 63: 1040–4, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Matur Z, Ucok A. Quetiapine treatment in a patient with Tourette's syndrome, obsessive-compulsive disorder and drug-induced mania. Isr J Psychiatry Relat Sci 2003; 40: 150–2, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Scahill L, Leckman J F, Schultz R T, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003; 60: 1130–5, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Stein D J, Bouwer C, Hawkridge S, Emsley R A. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997; 58: 119–22, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Boachie A, Goldfield G S, Spettigue W. Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports. Int J Eat Disord 2003; 33: 98–103, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ercan E S, Copkunol H, Cykoethlu S, Varan A. Olanzapine treatment of an adolescent girl with anorexia nervosa. Hum Psychopharmacol 2003; 18: 401–3, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hansen L. Olanzapine in the treatment of anorexia nervosa. Br J Psychiatry 1999; 175: 592, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Jensen V S, Mejlhede A. Anorexia nervosa: treatment with olanzapine. Br J Psychiatry 2000; 177: 87, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• LaMC Via, Gray N, Kaye W H. Case reports of olanzapine treatment of anorexia nervosa. Int J Eat Disord 2000; 27: 363–6, [CSA], [CROSSREF]
   Google Scholar
• Malina A, Gaskill J, McConaha C, et al. Olanzapine treatment of anorexia nervosa: a retrospective study. Int J Eat Disord 2003; 33: 234–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mehler C, Wewetzer C, Schulze U, et al. Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. Eur Child Adolesc Psychiatry 2001; 10: 151–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Powers P S, Santana C A, Bannon Y S. Olanzapine in the treatment of anorexia nervosa: an open label trial. Int J Eat Disord 2002; 32: 146–54, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ashton A K. Olanzapine augmentation for trichotillomania. Am J Psychiatry 2001; 158: 1929–30, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bai Y, Yu S, Lin C. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64: 1342–8, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bourgeois J A, Klein M. Risperidone and fluoxetine in the treatment of pedophilia with comorbid dysthymia. J Clin Psychopharmacol 1996; 16: 257–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cetin M, Ebrinc S, Agargun M Y, Yigit S. Risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Clin Psychiatry 1999; 60: 554, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Fawcett R G. Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis. J Clin Psychiatry 2002; 63: 169, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Gallucci G, Beard G. Risperidone and the treatment of delusions of parasitosis in an elderly patient. Psychosomatics 1995; 36: 578–80, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand 2002; 105: 441–4, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Phillips K A, Albertini R S, Siniscalchi J M, Khan A, Robinson M. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry 2001; 62: 721–7, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Potenza M N, Wasylink S, Epperson C N, McDougle C J. Olanzapine augmentation of fluoxetine in the treatment of trichotillomania. Am J Psychiatry 1998; 155: 1299–300, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Safer D L, Wenegrat B, Roth W T. Risperidone in the treatment of delusional parasitosis: a case report. J Clin Psychopharmacol 1997; 17: 131–2, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Stein D J, Bouwer C, Hawkridge S, Emsley R A. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997; 58: 119–22, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Stewart R S, Nejtek V A. An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. J Clin Psychiatry 2003; 64: 49–52, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Weintraub E, Robinson C. A case of monosymptomatic hypochondriacal psychosis treated with olanzapine. Ann Clin Psychiatry 2000; 12: 247–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Zuddas A, Cianchetti C. Efficacy of risperidone in idiopathic segmental dystonia. Lancet 1996; 347: 127–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar